RESUMEN
In previous work, we have demonstrated that vascular targeting of [213Bi], an alpha-emitter, to lung blood vessels could efficiently destroy tumour colonies growing in the lung. In order to expand this approach to treatment of tumours growing in other sites, we employed the monoclonal antibody (MAb) TES-23, which reacts with CD44H, preferentially expressed on new blood vessels in tumours. Biodistribution studies of N-succinimidyl [125I] 3-iodobenzoate (SIB)-radiolabelled MAb TES-23 in ICR-severe combined immunodeficient (SCID) mice bearing subcutaneous (s.c.) and intramuscular (i.m.) IC-12 tumours, demonstrated efficient tumour uptake. At 24 h, accumulation in small tumours was 45%ID/g for s.c. tumours, and 58%ID/g for i.m. tumours and in large tumours it was 25%ID/g for s.c. tumours and 17%ID/g for i.m. tumours. Micro-autoradiography data confirmed that radiolabel accumulated in or near tumour blood vessels. Normal tissues had very low levels of radioactivity. Treatment of mice bearing small IC-12 tumours with [213Bi] MAb TES-23 retarded tumour growth relative to animals treated with cold MAb TES-23. Biodistribution and therapy experiments were also performed in BALB/c mice bearing both s.c. and i.m. syngeneic, lung carcinoma (line 498) tumours. [I(125)] SIB MAb TES-23 accumulated efficiently in both s.c. and i.m. tumours (14%ID/g and 15%ID/g, respectively, at 4 h); however, no therapeutic effect of [213Bi] MAb TES-23 treatment could be demonstrated in this model system. The data demonstrate that the timing of vascularisation of the tumours and the delivery kinetics of MAb relative to the half-life of the therapeutic radionuclide are critical for effective therapy.
Asunto(s)
Bismuto/uso terapéutico , Radioinmunoterapia/métodos , Radioisótopos/uso terapéutico , Neoplasias de la Tráquea/radioterapia , Animales , Anticuerpos Monoclonales/farmacocinética , Autorradiografía , Bismuto/farmacocinética , Western Blotting , División Celular , Ratones , Ratones Endogámicos BALB C , Ratones SCID , Trasplante de Neoplasias , Radioisótopos/farmacocinética , Ratas , Neoplasias de la Tráquea/irrigación sanguínea , Neoplasias de la Tráquea/patología , Trasplante HeterólogoRESUMEN
Immunoconjugate targeting of solid tumors has not been routinely successful because the endo-thelial cells of blood vessels act as a physical barrier against the transport of macromolecules, such as antibodies. In the present study, we attempted to achieve tumor vascular targeting with an anti-tumor tissue endothelium-specific monoclonal antibody (TES-23). TES-23, an IgG1 monoclonal antibody raised against rat KMT-17 fibrosarcoma-derived endothelial cells, was covalently conjugated with neocarzinostatin (NCS) in a previous study. The TES-23-NCS conjugate induced tumor hemorrhagic necrosis, and showed marked anti-tumor effects against rat KMT-17 fibrosarcoma. This result prompted us to investigate whether this approach would be applicable to various other types of solid tumors. One hour after injection of (125)I-labeled TES-23 into BALB / c mice bearing Meth-A fibrosarcoma and Colon 26 adenocarcinoma, the tumor accumulation of TES-23 was greater than that of the control IgG. In the present study, we report the anti-tumor effects of this monoclonal antibody in mice bearing Meth-A fibrosarcoma. Mice treated with the immunoconjugate showed improved survival with no side effects. This result indicates that common antigens may be found in different kinds of tumor endothelial cells, and that TES-23 might recognize these antigens.
Asunto(s)
Anticuerpos Monoclonales/farmacocinética , Endotelio Vascular/inmunología , Fibrosarcoma/tratamiento farmacológico , Fibrosarcoma/radioterapia , Radioisótopos de Yodo/uso terapéutico , Cinostatina/uso terapéutico , Animales , Anticuerpos Monoclonales/uso terapéutico , Especificidad de Anticuerpos , Peso Corporal , Femenino , Fibrosarcoma/irrigación sanguínea , Hemorragia , Inmunoglobulina G , Radioisótopos de Yodo/farmacocinética , Ratones , Ratones Endogámicos BALB C , Necrosis , Radioinmunoterapia/métodos , Ratas , Distribución Tisular , Cinostatina/farmacocinéticaRESUMEN
Endothelial cells in solid tumors play an important role in tumor growth, invasion and metastasis through angiogenesis. We have recently cloned two tumor vascular antigens from isolated rat tumor vascular endothelial cells (TEC). One is CD44, a family of cell surface proteins implicated in adhesion interactions and tumor metastasis. The other is OTS-8, a marker for osteoblast into osteocyte transition and type I alveolar epithelial cells termed as E11 antigen and RTI40, respectively. To test for a possible interaction between the two antigens on endothelial cells in tumor angiogenesis, we examined in vivo association of CD44 with OTS-8 using lysates of isolated rat TEC and COS-7 cells cotransfected with CD44 and OTS-8 expression plasmids. The association was detected by direct co-immunoprecipitation of the two types of cells lysed with digitonin, whereas the detection was lost when lysed with Nonidet P-40. To confirm this association, intact COS-7 cells cotransfected were reacted with homobifunctional N-hydroxysuccinimide ester crosslinking reagents. Immunoblot analysis showed a crosslinked CD44/OTS-8 protein complex of 120 kDa, suggesting the proximity of the two proteins. These findings provide evidence of a weak physical association between CD44 and OTS-8 in TEC, and suggest that OTS-8 may alter the mode of endothelial cell growth and/or migration induced by CD44 in tumor angiogenesis.
Asunto(s)
Endotelio Vascular/metabolismo , Receptores de Hialuranos/metabolismo , Proteínas de la Membrana/metabolismo , Animales , Biomarcadores , Células COS , Reactivos de Enlaces Cruzados , Receptores de Hialuranos/genética , Glicoproteínas de Membrana , Proteínas de la Membrana/genética , Plásmidos , Pruebas de Precipitina , Ratas , Succinimidas , Transfección , Células Tumorales CultivadasRESUMEN
We have previously prepared monoclonal antibodies (MAbs) against tumor vasculature using cultured rat tumor endothelial cells (TECs) isolated from solid KMT-17 tumors and identified 40 and 80 kDa antigens recognized by TES-17 and TES-23 MAbs, respectively. To clarify the nature of antigens on tumor vasculature, molecular cloning was conducted by screening the rat TEC cDNA library. Two antigens were detected: a 40 kDa OTS-8 antigen, which had been defined as a differentiation marker for osteoblastic lineage, and an 80 kDa CD44H antigen. Northern blots showed that OTS-8 mRNA was expressed exclusively in the lung, in addition to TECs, while CD44H mRNA was detected in the lung, intestine, spleen, thymus and peripheral blood cells, in addition to TECs. Immuno-histochemistry of KMT-17 tumors revealed that OTS-8 and CD44 were expressed on sprouting TECs. In addition, TES-23 MAb stained TECs of tubular vessels as well as sprouting TECs, but anti-rat CD44 MAbs stained only sprouting TECs. PCR showed that CD44 cDNA with a splice in exon 6 (CD44ex6) was present in rat TECs at low levels. Our results indicate that OTS-8 and CD44 are expressed on rat sprouting TECs and that TES-23 MAb recognizes CD44H on sprouting TECs as well as an unknown epitope on TECs of tubular vessels that could not be recognized by anti-rat CD44 MAbs.
Asunto(s)
Antígenos de Neoplasias/análisis , Endotelio Vascular/inmunología , Neoplasias Experimentales/irrigación sanguínea , Animales , Anticuerpos Monoclonales/inmunología , Antígenos de Neoplasias/genética , Secuencia de Bases , Células COS , Clonación Molecular , Endotelio Vascular/citología , Receptores de Hialuranos/análisis , Receptores de Hialuranos/genética , Datos de Secuencia Molecular , Peso Molecular , RatasRESUMEN
TES-23 monoclonal antibody (MAb), which targets rat CD44H on tumor vascular endothelial cells (TEC), dominantly reacted to human activated CD44 rather than human inactive CD44. TES-23 MAb reacted to HT-1080 fibrosarcoma cells almost comparably to anti-human CD44 MAb and moderately to HUVEC; however, it hardly reacted to PBMC. The binding of soluble hyaluronate to HT-1080 cells and HUVEC was clearly noted, but not to PBMC. In addition, stimulation with phorbol 12-myristate 13-acetate induced soluble hyaluronate binding of MOLT-4 human T lymphoma cells and relatively increased the reactivity of TES-23 MAb. Our results suggest that TES-23 MAb can potentially recognize human activated CD44 and hence might be potentially useful for the treatment of human solid tumors containing TEC that express activated CD44.
Asunto(s)
Antígenos CD/fisiología , Endotelio Vascular/inmunología , Receptores de Hialuranos/análisis , Receptores de Hialuranos/fisiología , Linfocitos/inmunología , Animales , Anticuerpos Monoclonales , Especificidad de Anticuerpos , Antígenos CD/análisis , Células Cultivadas , Endotelio Vascular/citología , Fibrosarcoma , Citometría de Flujo , Humanos , Linfocitos/citología , Ratas , Células Tumorales Cultivadas , Venas UmbilicalesRESUMEN
The tissue distribution of anti-tumour vascular endothelium monoclonal antibody (TES-23) produced by immunizing with plasma membrane vesicles from isolated rat tumour-derived endothelial cells (TECs) was assessed in various tumour-bearing animals. Radiolabelled TES-23 dramatically accumulated in KMT-17 fibrosarcoma, the source of isolated TECs after intravenous injection. In Meth-A fibrosarcoma, Colon-26 adenocarcinoma in BALB/c mice and HT-1080 human tumour tissue in nude mice, radioactivities of 125I-labelled TES-23 were also up to 50 times higher than those of control antibody with little distribution to normal tissues. The selective recognition of TES-23 to TECs was competitively blocked by preadministration of unlabelled TES-23 in vivo. Furthermore, immunostaining of human tissue sections showed specific binding of TES-23 on endothelium in oesophagus cancers. These results indicate that tumour vascular endothelial cells express common antigen in different tumour types of various animal species. In order to clarify the efficacy of TES-23 as a drug carrier, an immunoconjugate, composed of TES-23 and neocarzinostatin, was tested for its anti-tumour effect in rats bearing KMT-17 fibrosarcomas. The immunoconjugate (TES-23-NCS) caused marked regression of the tumour, accompanied by haemorrhagic necrosis. Thus, from a clinical view, TES-23 would be a novel drug carrier because of its high specificity to tumour vascular endothelium and its application to many types of cancer.
Asunto(s)
Adenocarcinoma/metabolismo , Anticuerpos Monoclonales/metabolismo , Reacciones Antígeno-Anticuerpo , Sistemas de Liberación de Medicamentos , Endotelio Vascular/inmunología , Fibrosarcoma/metabolismo , Animales , Especificidad de Anticuerpos , Portadores de Fármacos , Femenino , Humanos , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Ratas , Distribución TisularRESUMEN
We have reported that immunization of rat tumor-derived endothelial cells (TEC) isolated from KMT-17 solid tumors results in the generation of several monoclonal antibodies (MAbs). TES-23, one of these MAbs, recognizes a naturally occurring 80-kDa antigen expressed on endothelial cells of tumor blood vessels. To determine whether such MAbs can suppress solid tumor growth in vivo by impairment of endothelial cells in tumors following direct binding, we tested the biodistribution of (125)I-labeled TES-23 in rats bearing KMT-17 solid tumors. We also examined the effect of treatment using unconjugated TES-23 on tumor growth and histo-pathological changes in tumor tissues. Biodistribution studies showed localization of TES-23 into tumor tissues 60 min after intravenous injection. TES-23 suppressed significantly the growth of KMT-17 solid tumors following administration for 5 days. Histo-pathological examination showed that TES-23 caused degeneration, apoptosis and/or necrosis and denudation of endothelial cells in viable tumor areas following local aggregation and adhesion of lymphocytes, with subsequent intravascular thrombus formation by platelets and fibrin. Our results indicate that TES-23, which recognizes TEC, can target endothelial cells of solid tumor vasculature directly, resulting in growth suppression in vivo by reduction of blood flow due to intravascular thrombosis. Our results also suggest that targeting tumor vasculature is a potentially attractive approach for the treatment of solid tumors.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Endotelio Vascular/inmunología , Fibrosarcoma/terapia , Neovascularización Patológica/inmunología , Animales , Anticuerpos Monoclonales/farmacocinética , Recuento de Células Sanguíneas , Adhesión Celular , Agregación Celular , División Celular , Supervivencia Celular , Cisplatino/uso terapéutico , Endotelio Vascular/patología , Femenino , Fibrosarcoma/sangre , Fibrosarcoma/irrigación sanguínea , Fibrosarcoma/patología , Hematócrito , Hemoglobinas/análisis , Radioisótopos de Yodo/farmacocinética , Linfocitos/fisiología , Ratas , Ratas Endogámicas , Sarcoma Experimental/sangre , Sarcoma Experimental/irrigación sanguínea , Sarcoma Experimental/patología , Sarcoma Experimental/terapia , Distribución TisularRESUMEN
In this study, we attempted to develop tumor vascular targeting with a tumor tissue endothelium-specific monoclonal antibody. TES-23, which strongly and selectively recognizes tumor tissue endothelial cells, was chemically conjugated with Neocarzinostatin (NCS), and the anti-tumor effect was examined. The immunoconjugate, TES-23-NCS, showed, through the use of tumor hemorrhagic necrosis, a marked anti-tumor effect on KMT-17 tumors in rats at a dosage of 17 micrograms/kg (NCS equivalent) without any side effects, probably due to specific tumor vascular injury. By contrast, TES-23 alone (107 micrograms/kg), NCS alone (17 micrograms/kg), and Mopc-NCS (Mopc, 107 micrograms/kg; NCS, 17 micrograms/kg), the immunoconjugate of control antibody, did not have any anti-tumor activities. By tissue distribution analysis, TES-23 and TES-23-NCS showed high accumulation in KMT-17 tumors 1 h after intravenous administration. Moreover TES-23 also accumulated in Sarcoma-180 tumors in mice 1 h after intravenous administration. These results suggest that TES-23 may be a candidate for a potential tumor vascular targeting agent that is applicable to a wide variety of tumor types.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Antineoplásicos/uso terapéutico , Endotelio Vascular/inmunología , Neoplasias Experimentales/tratamiento farmacológico , Animales , Anticuerpos Monoclonales/farmacocinética , Antineoplásicos/administración & dosificación , Antineoplásicos/farmacocinética , Portadores de Fármacos , Femenino , Ratones , Ratas , Distribución TisularRESUMEN
We have reported the isolation and specific in vitro properties of tumor-derived endothelial cells (TEC) from rat KMT-17 fibrosarcomas transplanted into rats. To develop antibody-based tumor vascular targeting therapy for solid tumors, we have generated monoclonal antibodies (MAbs) using passive immunization of outside-out membrane vesicles of rat epididymal-fat-pad-derived capillary endothelial cells (FCEC) followed by active immunization of those of rat TEC. The MAbs produced were screened against TEC and FCEC. Of all cultured hybridomas, 75 (3.3%) of the secreted MAbs preferentially recognized TEC. We selected a total of 7 MAbs which detected antigens highly abundant in TEC, although 5 of the 7 MAbs were weakly positive for FCEC in cell-ELISA and FACS analyses. The antigens recognized by these MAbs, with the exception of MAb TES-7, were present on endothelial cells of tumor blood vessels in KMT-17 fibrosarcoma tissues, as shown by immunohistochemical analysis. Antigens of 40- and 80-kDa were recognized by MAbs TES-1, 7, 17, 21 and 26 and by MAbs TES-23 and 27 respectively. Although the function of these antigens, which are preferentially expressed on rat tumor-derived endothelial cells, is still unknown, we believe that future studies of such antigens will help elucidate the role of endothelial cells in tumor vasculature. Our results indicate that MAbs may provide a novel tool for the development of antibody-based therapy targeting tumor vasculature.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Antígenos de Neoplasias/análisis , Endotelio Vascular/inmunología , Fibrosarcoma/inmunología , Animales , Antígenos de Neoplasias/inmunología , Western Blotting , Capilares/inmunología , Carcinógenos , Femenino , Fibrosarcoma/inducido químicamente , Citometría de Flujo , Hibridomas/inmunología , Metilcolantreno , Ratones , Ratones Endogámicos BALB C , RatasRESUMEN
We have developed a new approach to antibody-based therapy of solid tumors by targeting tumor vascular endothelial cells (EC) which are essential for the growth of solid tumors. We investigated the effect of an antibody against tumor-derived endothelial cells (TEC) on the growth of solid tumors in rats. Intravenous administration of TES-23, a monoclonal antibody generated by TEC isolated from rat KMT-17 solid tumors, at 1 mg/rat/day for 5 days resulted in significant suppression of KMT-17 tumor growth. Histopathological analysis of tumors administered with TES-23 showed that adhesion of lymphocytes to EC followed by denudation of EC in the viable tumor area. In contrast, little obvious toxicity was observed in most of the rat organs examined. These findings suggest that the concept of an antibody-based therapy with targeting tumor vascular EC would be promising in treatment of solid tumors.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Endotelio Vascular/inmunología , Sarcoma Experimental/terapia , Animales , Citotoxicidad Celular Dependiente de Anticuerpos , Endotelio Vascular/citología , Femenino , Inmunoterapia , Ratas , Sarcoma Experimental/irrigación sanguínea , Sarcoma Experimental/patologíaRESUMEN
Previously, we reported that a novel styryl diphenylamine derivative, RX-465, reverts the transformed phenotype of human fibrosarcoma HT1080 cells in vitro. To determine whether agents inducing such phenotypic reversion show antitumor and/or antimetastatic effects in vivo, we assessed tumor growth and metastasis in mice inoculated with either murine B16-, B16BL6 melanoma or M5076 reticulosarcoma. These mice received orally our new derivatives of RX-465, namely RX-512 and RX-549. We found that these-derivatives inhibited B16 melanoma and M5076 reticulosarcoma growth by greater than 80% in vivo. RX-512 also inhibited the metastatic dissemination of B16BL6 melanoma into the lung and that of M5076 reticulosarcoma into the liver by 98% and 100% at doses of 60 and 40 mg/kg/day, respectively. These treatments did not cause significant decreases in body weight. Our data strongly demonstrate that styryl diphenylamine derivatives that revert transformed phenotype in vitro potentially inhibit tumor growth and metastasis in mice with negligible toxicity at effective doses.
Asunto(s)
Antineoplásicos/farmacología , Difenilamina/análogos & derivados , Metástasis de la Neoplasia/prevención & control , Neoplasias Experimentales/tratamiento farmacológico , Niacina/análogos & derivados , Animales , División Celular/efectos de los fármacos , Difenilamina/farmacología , Melanoma Experimental/tratamiento farmacológico , Melanoma Experimental/patología , Ratones , Ratones Endogámicos C57BL , Neoplasias Experimentales/patología , Niacina/farmacología , Sarcoma Experimental/tratamiento farmacológico , Sarcoma Experimental/patología , Células Tumorales CultivadasRESUMEN
Revertant cells, which can be isolated from transformed cells, are flat, non-transformed variants that have contributed to the elucidation of mechanisms involved in cell transformation. We have discovered that a novel styryl diphenylamine derivative converts human fibrosarcoma HT1080 cells into revertant cells. This compound induces flat cell morphology and causes a decrease in proliferative rate. The flat revertant cells not only exhibit a reduction in saturation density at confluence, but also lose the ability to proliferate in soft agar. Furthermore, their tumorigenicity is reduced when injected s.c. into athymic nude mice. The compound alters morphology in three out of seven cancer cell lines and has a potent growth inhibitory effect in six of these lines. In contrast, it has only low levels of cytotoxicity for three normal diploid cell lines. These findings indicate that this styryl diphenylamine derivative has the potential to suppress the malignant phenotype of cancer cells without profound cytotoxicity in non-transformed cells.